---
title: "Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline"
description: "Isomorphic Labs' president says its AI hypothesis \"has been proven.\" The ledger shows $2.7 billion raised, $82.5 million banked from partners, no drug named and no trial started, with the company's own year-end deadline 13 weeks away."
publisher: "The Inference"
section: "Health"
published: 2026-10-02T16:03:48.824Z
modified: 2026-10-02T16:03:48.824Z
canonical: https://theinference.org/article/isomorphic-says-its-ai-is-proven-2-7-billion-rides-on-a-31-december-deadline
language: en
keywords: "AI Drug Discovery, Biotech, Isomorphic Labs, Alphabet, Clinical Trials"
---

# Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline

> Isomorphic Labs' president says its AI hypothesis "has been proven." The ledger shows $2.7 billion raised, $82.5 million banked from partners, no drug named and no trial started, with the company's own year-end deadline 13 weeks away.

## The charge: proven, with 13 weeks left

On 29 September [Isomorphic Labs](https://theinference.org/markets/companies/isomorphic-labs) president Max Jaderberg declared the company's founding wager settled: "Our hypothesis has been proven" [1][2]. [The manifesto](https://www.isomorphiclabs.com/articles/building-a-new-path-to-make-medicines-with-ai) shows IsoDDE, the drug design engine, searching chemical space for an unnamed "Target D" in two to four days, against a published reference molecule its authors estimate took three to five years of work [1]. The company's own test sits 13 weeks out: a first clinical trial by the end of 2026, a deadline already moved once from late 2025 [2].

## The evidence admitted: $2.7 billion in, $82.5 million banked

About $2.7 billion of outside money has arrived since 2025, a $600 million first round and then [a $2.1 billion Series B in May led by Thrive Capital](https://pharmaphorum.com/news/isomorphic-raises-21bn-ai-drug-hunt) with [Alphabet](https://theinference.org/markets/companies/alphabet), GV and Temasek [2][4]. The disclosed partner income, ever, is $82.5 million in upfronts: $45 million from [Eli Lilly](https://theinference.org/markets/companies/eli-lilly) and $37.5 million from [Novartis](https://theinference.org/markets/companies/novartis), both signed January 2024, against up to $2.9 billion in contingent milestones [2]. Not one milestone payment has been reported [2].

The disclosure record is thin. As of 30 September, [Isomorphic](https://theinference.org/markets/companies/isomorphic-labs) had named no candidate, named no target, given no program count, filed no IND and started no trial; the only pipeline detail on offer is two focus areas, oncology and immunology [2].

*Chart: **Isomorphic has banked $82.5M of partner cash; not one milestone paid** Bars comparing Isomorphic Labs' funding raised and partner deal ceilings against the upfronts actually received*

*US$ millions. Deal terms and financing as reported by BiopharmaTrend and pharmaphorum; milestone figures are contractual ceilings contingent on R&D success, not cash received. Funding is the $600M 2025 round plus the $2.1B Series B of May 2026. [2][4]*

## The exhibits: partners who come back

Pharma keeps signing back. Novartis added up to three programs a year after its first deal, and Johnson & Johnson [signed a cross-modality, multi-target collaboration on 20 January 2026](https://www.isomorphiclabs.com/articles/isomorphic-labs-enters-into-a-research-collaboration-with-johnson-johnson), terms undisclosed [2][5]. In February the company published benchmarks claiming more than double AlphaFold 3's accuracy on hard protein-ligand cases [2].

## The cross-examination: the candidate was Insilico's

Skeptic Melinda Chu's line is blunt: "you can't cure a disease without a drug" [2]. On 30 September [a crypto news wire ran a nomination under Isomorphic's name: ISM1354](https://www.gate.com/fr/news/detail/isomorphic-labs-nominates-ism1354-next-generation-gipr-antagonist-reaching-24650776), a GIPR antagonist for obesity and type 2 diabetes, a 34th preclinical candidate since 2021 [6]. [The release](https://www.prnewswire.com/news-releases/breaking-the-safety-barrier-insilico-medicine-nominates-ism1354-the-next-generation-small-molecule-gipr-antagonist-302893899.html) belongs to Insilico Medicine, which took rentosertib from target to Phase 1 in under 30 months and is now in Phase 3 [2][8]. Insilico, listed in Hong Kong, booked its first profitable half-year in 2026 on about $106 million of revenue [8].

## The trade: three tickers hold the test

Eli Lilly (LLY) and Novartis (NVS) paid to see the internal data and hold the milestone schedules, Lilly up to $1.7 billion and Novartis up to $1.2 billion [2]. A first milestone cheque would be the first independent confirmation the engine works [2]. Alphabet (GOOGL) owns the lab outright and funded it before outside money arrived [2][3]. The listed comp is Schrödinger (SDGR): $199.5 million of 2025 software revenue against a $103 million net loss, and it sells what Isomorphic does not [2]. Miss 31 December again and [the AI premium](https://theinference.org/article/iambic-hands-its-cancer-pill-gamble-to-nasdaq-after-461-8m-of-private-money) deflates; hit it and the partner programs move.

## The verdict watch: 31 December

Three receipts would settle the argument: an IND filing, a trial start, or the first milestone payment [2]. The trade watches the same list, so milestone news or an IND out of the Lilly and Novartis programs before 31 December is the signal. Chu predicts no trial this year, and possibly not in 2027; the company's own clock says otherwise [2].

## Takeaway

Isomorphic Labs calls its AI hypothesis proven, but the record shows $82.5 million of partner cash banked, no drug named and no trial started; the company's own 31 December deadline for a first clinical trial is when the argument settles.

## Sources

1. [Isomorphic Labs, "Building a new path to make medicines with AI", 29 September 2026](https://www.isomorphiclabs.com/articles/building-a-new-path-to-make-medicines-with-ai)
2. [BiopharmaTrend, "The $2.7B Question: How Do We Know If Isomorphic's AI Works?", 30 September 2026](https://www.biopharmatrend.com/business-intelligence/the-27b-question-how-do-we-know-if-isomorphics-ai-works/)
3. [Wikipedia, "Isomorphic Labs", retrieved 2 October 2026](https://en.m.wikipedia.org/wiki/Isomorphic_Labs)
4. [pharmaphorum, "Isomorphic raises $2.1bn for AI drug hunt", 12 May 2026](https://pharmaphorum.com/news/isomorphic-raises-21bn-ai-drug-hunt)
5. [Isomorphic Labs, "Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson", 20 January 2026](https://www.isomorphiclabs.com/articles/isomorphic-labs-enters-into-a-research-collaboration-with-johnson-johnson)
6. [Gate News (FR), "Isomorphic Labs annonce la sélection de l'ISM1354...", 30 September 2026](https://www.gate.com/fr/news/detail/isomorphic-labs-nominates-ism1354-next-generation-gipr-antagonist-reaching-24650776)
8. [PR Newswire (Insilico Medicine), "Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354", 30 September 2026](https://www.prnewswire.com/news-releases/breaking-the-safety-barrier-insilico-medicine-nominates-ism1354-the-next-generation-small-molecule-gipr-antagonist-302893899.html)


---

Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline — The Inference. Canonical: https://theinference.org/article/isomorphic-says-its-ai-is-proven-2-7-billion-rides-on-a-31-december-deadline
